Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update

Sasanka Handunnetti • 7 Dec 2019
ASH 2019
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Venetoclax
AIM

Sasanka Handunnetti, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, outlines the rationale and results of the AIM trial (NCT02471391), investigating the combination of ibrutinib and venetoclax in relapsed/refractory mantle cell lymphoma (MCL). Results from this three-year update are promising and demonstrate that ibrutinib in combination with venetoclax offers durable responses to patients who otherwise have limited durable therapeutic options. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sasanka Handunnetti

3:35
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Sasanka Handunnetti • 20 Jun 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals